Skip to content

Advertisement

  • Invited speaker presentation
  • Open Access

FMF: an update

  • 1
Pediatric Rheumatology201412 (Suppl 1) :I33

https://doi.org/10.1186/1546-0096-12-S1-I33

  • Published:

Keywords

  • Public Health
  • Clinical Symptom
  • Acute Phase
  • Colchicine
  • Chronic Inflammation

Familial Mediterranean fever (FMF) is the most common autoinflammatory disease over the world. This autosomal recessively inherited disease is due to mutations in the gene coding for pyrin. Disease causing mutations in the gene are associated with excessive levels of IL-1. The clinical symptoms of inflammation are mainly in the form of fever and serositis along with laboratory evidence of persistently raised acute phase reactants, including serum amyloid A levels. Untreated patients suffer the consequences of chronic inflammation.

Patients who display inflammatory symptoms but who carry one mutation only should be carefully evaluated for the need of therapy. Colchicine is the main treatment of FMF. Management of the patients includes following clinical activity of the disease and acute phase reactants on a regular basis and checking for drug compliance, and monitoring side effects of the drug. If patients are intolerant to or unresponsive to colchicine anti IL1 treatment should be considered.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
Pediatric Rheumatology, Hacettepe University, Ankara, Turkey

Copyright

© Ozen; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement